INOZYME PHARMA INC (INZY) Forecast, Price Target & Analyst Ratings
NASDAQ:INZY • US45790W1080
4 USD
+0.01 (+0.25%)
At close: Jun 30, 2025
3.99 USD
-0.01 (-0.25%)
After Hours: 6/30/2025, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INOZYME PHARMA INC (INZY).
Forecast Snapshot
Consensus Price Target
$6.85
+ 71.21% Upside
Next Earnings Forecast
Release DateAug 4, 2025
PeriodQ2 / 2025
EPS Estimate-$0.37
Revenue Estimate
ChartMill Buy Consensus
72.31%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$6.85
Upside
+ 71.21%
From current price of $4.00 to mean target of $6.85, Based on 13 analyst forecasts
Low
$4.04
Median
$4.08
High
$16.80
Price Target Revisions
1 Month
0.00%
3 Months
-50.26%
Price Target Summary
13 Wall Street analysts provided a forecast for the next 12 months for INZY. The average price target is 6.85 USD. This implies a price increase of 71.21% is expected in the next year compared to the current price of 4.
The average price target has been revised downward by 50.26% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
72.31%
INZY was analyzed by 13 analysts. The buy percentage consensus is at 72. So analysts seem to be have mildly positive about INZY.
In the previous month the buy percentage consensus was at a similar level.
INZY was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-05-16 | Needham | Downgrade | Buy -> Hold |
| 2025-05-16 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-05-16 | Jefferies | Downgrade | Buy -> Hold |
| 2025-05-14 | Needham | Maintains | Buy -> Buy |
| 2025-04-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-03-12 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-03-11 | Needham | Maintains | Buy -> Buy |
| 2025-03-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-01-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-01-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-06 | Needham | Reiterate | Buy -> Buy |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-25 | Needham | Reiterate | Buy -> Buy |
| 2024-10-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-30 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-09-12 | Stifel | Initiate | Buy |
| 2024-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-06 | Needham | Reiterate | Buy -> Buy |
| 2024-07-26 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-07-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-30 | Wells Fargo | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateAug 4, 2025
PeriodQ2 / 2025
EPS Estimate-$0.37
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q16.48%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-0.01%
EPS (3 Months)
-3.31%
Next Earnings Summary
INZY is expected to report earnings on 8/4/2025. The consensus EPS estimate for the next earnings is -0.37 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 3,284.07% | N/A 229.59% | N/A 59.16% | N/A 73.86% | N/A 42.12% | N/A 32.68% | ||||||||
| EBITDA YoY % growth | -11.56M | -20.73M -79.33% | -56.82M -174.10% | -55.98M 1.48% | -67.94M -21.36% | -74.812M -10.11% | -103.288M -38.06% | N/A 6.70% | N/A -23.62% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.59M | -20.81M -79.55% | -57.04M -174.10% | -56.65M 0.68% | -68.68M -21.24% | -75.645M -10.14% | -104.03M -37.52% | N/A 0.18% | N/A -15.60% | N/A 8.73% | N/A -0.69% | N/A 45.32% | N/A 186.38% | N/A 307.61% | N/A 53.86% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.39 49.64% | -1.89 20.92% | -1.37 27.51% | -1.62 -18.25% | N/A 9.62% | N/A 19.94% | N/A 31.80% | N/A 92.34% | N/A 600.00% | N/A 63.33% | N/A 36.73% | N/A 10.45% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 16.48% | -0.34 13.32% | -0.36 12.52% | -0.32 28.14% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -19.451M 28.74% | -17.228M 29.06% | -32.273M -22.11% | N/A |
| EBIT Q2Q % growth | -24.924M 9.91% | -24.653M 0.80% | -26.843M 1.21% | -29.728M -15.28% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
14.64%
EPS Next 5 Year
16.96%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
INOZYME PHARMA INC / INZY Forecast FAQ
What is the average price target for INOZYME PHARMA INC (INZY) stock?
13 analysts have analysed INZY and the average price target is 6.85 USD. This implies a price increase of 71.21% is expected in the next year compared to the current price of 4.
Can you provide the upcoming earnings date for INOZYME PHARMA INC?
INOZYME PHARMA INC (INZY) will report earnings on 2025-08-04, before the market open.
What are the consensus estimates for INOZYME PHARMA INC (INZY) next earnings?
The consensus EPS estimate for the next earnings of INOZYME PHARMA INC (INZY) is -0.37 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for INOZYME PHARMA INC (INZY) stock?
The consensus rating for INOZYME PHARMA INC (INZY) is 72.3077 / 100 . This indicates that analysts generally have a positive outlook on the stock.